Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02120105
Other study ID # 6402
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 2012
Est. completion date February 24, 2017

Study information

Verified date November 2018
Source New York University School of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to determine whether urinary cystine capacity, an assay used to measure the amount of cystine in the urine, can be used to predict stone recurrence in patients with cystinuria.


Description:

Cystinuria is a rare genetic cause of kidney stones that leads to significant morbidity due to the recurrent nature of the disease. Despite recent advancements in knowledge about cystinuria, such as the discovery of the genetic defects that cause the disease, there have been very few studies of clinical determinants of recurrent stone formation. An optimal method of measuring cystine solubility in the urine has been lacking, and therefore response to pharmacologic and dietary therapy is often not known. Recently, a new assay to measure the amount of cystine in the urine was developed called Cystine Capacity, or CysCap. It is an assay that adds a pre-formed amount of cystine crystals to urine and measures the amount of cystine the urine can take up from the solid phase (in undersaturated urine) or gives up to solid phase (in supersaturated urine). This study seeks to examine how well this measure of urinary cystine predicts stone occurrence, with the ultimate goal of helping to guide therapy and preventing kidney stones in cystinurics.

This is an observational study over 3 years. Subjects who are enrolled in the study will perform semi-annual 24-hour urine collections. They will undergo imaging of the kidneys every 6 months to monitor kidney stone formation or growth, in order to correlate urinary parameters with clinical events. The study will examine how well the urinary cystine capacity predicts stone formation.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date February 24, 2017
Est. primary completion date February 24, 2017
Accepts healthy volunteers No
Gender All
Age group 8 Years to 80 Years
Eligibility Inclusion Criteria:

- Patients with a confirmed laboratory diagnosis of cystinuria will be included in this study. There will be no age barrier to inclusion, but included patients must be able to reliably collect urine for 24 hours. Men and women will be recruited equally and there are no restrictions for racial or ethnic origin in this study.

- Patient enrollment will require signing of an informed consent document approved by the Lenox Hill IRB.

- For children 8-18 years of age, signing an assent to participate will also be required.

Exclusion Criteria:

- Patients will be excluded if they cannot sign consent or assent.

- Furthermore if the patient cannot reliably collect urine for 24 hours or adhere to study follow up visit requirements.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States NYU Langone Medical Center New York New York

Sponsors (1)

Lead Sponsor Collaborator
New York University School of Medicine

Country where clinical trial is conducted

United States, 

References & Publications (1)

Goldfarb DS, Coe FL, Asplin JR. Urinary cystine excretion and capacity in patients with cystinuria. Kidney Int. 2006 Mar;69(6):1041-7. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Cystine capacity will be correlated with recurrence or non-recurrence of stones The primary end point will be cystine capacity in participants who do and do not have recurrence of stones seen on radiologic imaging in the ipsilateral kidney which was rendered stone-free prior to enrollment.
Subjects who are enrolled in the study will perform semi-annual 24-hour urine collections for measurement of cystine capacity. They will undergo imaging of the kidneys every 6 months to monitor kidney stone formation or growth, in order to correlate urinary parameters with clinical events.
every 6 months over 3 years
Secondary 24-hour urine cystine excretion We will compare 24 hour urine cystine excretion in patients who remain stone free and those who experience stone recurrence. every 6 months over 3 years
Secondary episodes of renal colic and/or stone passage from a kidney that was previously stone-free Assessed by renal imaging, either ultrasound or CT scan, every 6 months. every 6 months over 3 years
Secondary Evidence of new asymptomatic stones noted on the contralateral kidney Cystine capacity will be compared in participants with or without recurrence of stones in the contralateral kidney by renal ultrasound or CT scan every 6 months over 3 year observational study
See also
  Status Clinical Trial Phase
Completed NCT02538016 - TCUPS- Tolvaptan Use in Cystinuria and Urolithiasis: A Pilot Study N/A
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Recruiting NCT00169806 - Randall's Plaque Study: Pathogenesis and Relationship to Nephrolithiasis N/A
Completed NCT03663855 - Effect of Increasing Doses of Tiopronin on Cystine Capacity in Patients With Cystinuria Phase 2
Recruiting NCT02780297 - Prospective Research Rare Kidney Stones (ProRKS)
Recruiting NCT02026388 - Rare Kidney Stone Consortium Biobank
Recruiting NCT04818034 - The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study Phase 2
Withdrawn NCT04137978 - Study Evaluating Patients With Cystinuria Phase 2/Phase 3
Recruiting NCT02942420 - Bucillamine Phase 2 Trial in Patients With Cystinuria Phase 2
Completed NCT05048563 - Registry of Thiola EC Therapy
Not yet recruiting NCT04147871 - Study Evaluating Patients With Cystinuria and Efficacy and Safety Exploratory Study in the Youngest Children Phase 2/Phase 3
Completed NCT02125721 - Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria Phase 4
Active, not recruiting NCT02910531 - Lipoic Acid Supplement for Cystine Stone Phase 2
Recruiting NCT00588562 - Rare Kidney Stone Consortium Patient Registry
Completed NCT02124395 - Health-related Quality of Life in Rare Kidney Stone
Not yet recruiting NCT05058859 - Long Term Clinical Efficacy of Sodium-glucose Cotransporter-2 (SGLT-2) Inhibitor in Cystinurics Phase 2
Active, not recruiting NCT03539926 - This Study Evaluates the Superiority of Daily Self-pH Monitorization of Lit-control®pH Meter Compared to the Monitorization of Reactive Strips (Standard of Care). N/A
Completed NCT00381849 - Use of an Herbal Preparation to Prevent and Dissolve Kidney Stones Phase 1/Phase 2
Completed NCT03836144 - Effect of Urine Alkalinazation on Urinary Inflammatory Markers in Patients With Cystinuria

External Links